Mifepristone
Mifepristone is a progesterone receptor antagonist used primarily in combination with misoprostol for medical termination of an intrauterine pregnancy, according to approved gestational limits and local regulations. It works by blocking progesterone, a hormone essential for maintaining pregnancy, causing changes in the uterine lining and increasing the uterus’s sensitivity to prostaglandins. In certain countries and clinical settings, it is also used for specific conditions such as hyperglycaemia associated with endogenous Cushing’s syndrome. Mifepristone is available as oral tablets, with dosage and treatment protocols varying according to the indication. Possible side effects include abdominal pain, uterine cramping, vaginal bleeding, nausea, vomiting, diarrhoea, and headache. Its use requires appropriate medical assessment and supervision because of risks such as heavy bleeding, incomplete abortion, and ectopic pregnancy, which is not treated by mifepristone.
Mifepristone was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Mifepristone, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Mifepristone from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Mifepristone, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
